"Sigma-Aldrich is committed to the development of RNAi technology. Through our collaboration with TRC2, we're producing the most highly validated shRNA libraries available to the research community," said Dave Smoller, President of Sigma-Aldrich's Research Biotech Business Unit. "By making these tools available to researchers worldwide, Sigma-Aldrich is facilitating advanced disease and drug discovery research."
Lentiviral-based shRNA libraries enable researchers to study gene function and disease, both in standard cell lines and recognized difficult cell types such as primary, non-dividing, growth-arrested or terminally differentiated cells. Such cell lines are typically not amenable to standard transfection or genomic integration by other viral delivery systems, but they may be transduced efficiently with lentiviral particles.
"Over the coming years, The RNAi Consortium intends to build upon its successes with shRNA to facilitate loss-of-function genetic screens in mammalian cells," said David Root, Director of the RNAi Platform at the Broad Institute of MIT and Harvard and project leader for TRC2. "The existing TRC library has already proven highly effective for systematic viral-delivery RNAi screening. TRC2 will generate significant further improvements to the library and its applications."
The current MISSION(R) shRNA clone libraries comprise a comprehensive
collection of more than 160,000 pre-cloned lentiviral-based shRNA vector
constructs targeting more than 16,000 human genes (MISSION TRC-Hs1.0) and
16,000 mouse genes (MISSION TRC-Mm1.0). For more information about the
MISSION(R) shRNA clone collections, please visit us online at
Copyright©2008 PR Newswire.
All rights reserved